May 27, 2021 4:30pm EDT Sapience Therapeutics Enters Into Collaboration with National Cancer Institute (NCI) to Study ST101 Response in Specialized Tumor Models
May 18, 2021 4:05pm EDT Sapience Therapeutics Awarded SBIR Phase I Grant from National Institute of Allergy and Infectious Diseases
Apr 06, 2021 4:05pm EDT Sapience Therapeutics Announces Multiple Posters, Including Late-Breaker, at the American Association for Cancer Research (AACR) Annual Meeting 2021
Mar 04, 2021 8:30am EST Sapience Therapeutics to Present at the Upcoming 2021 Spring Private Company Showcase hosted by Credit Suisse, Solebury Trout, and Cooley
Aug 19, 2020 8:30am EDT Sapience Therapeutics Awarded SBIR Phase I Grant from National Cancer Institute
Aug 12, 2020 8:30am EDT Sapience Therapeutics Announces First Patient Dosed with ST101 in Phase 1/2 Study in Patients with Advanced Unresectable and Metastatic Solid Tumors
